Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection: a randomized trial

Autor: Jun Liu, Dan-Dan Li, Wei Dong, Yu-Qi Liu, Yang Wu, Da-Xuan Tang, Fu-Chun Zhang, Meng Qiu, Qi Hua, Jing-Yu He, Jun Li, Bai Du, Ting-Hai Du, Lin-Lin Niu, Xue-Jun Jiang, Bo Cui, Jiang-Bin Chen, Yang-Gan Wang, Hai-Rong Wang, Qin Yu, Jing He, Yi-Lin Mao, Xiao-Fang Bin, Yue Deng, Yu-Dan Tian, Qing-Hua Han, Da-Jin Liu, Li-Qin Duan, Ming-Jun Zhao, Cui-Ying Zhang, Hai-Ying Dai, Ze-Hua Li, Ying Xiao, You-Zhi Hu, Xiao-Yu Huang, Kun Xing, Xin Jiang, Chao-Feng Liu, Jing An, Feng-Chun Li, Tao Tao, Jin-Fa Jiang, Ying Yang, Yao-Rong Dong, Lei Zhang, Guang Fu, Ying Li, Shu-Wei Huang, Li-Ping Dou, Lan-Jun Sun, Ying-Qiang Zhao, Jie Li, Yun Xia, Fan Liu, Wen-Jin He, Jian-Cong Tan, Yang Lin, Ya-Bin Zhou, Jian-Fei Yang, Guo-Qing Ma, Hui-Jun Chen, He-Ping Liu, Zong-Wu Liu, Jian-Xiong Liu, Xiao-Jia Luo, Xiao-Hong Bin, Ya-Nan Yu, Hai-Xia Dang, Bing Li, Fei Teng, Wang-Min Qiao, Xiao-Long Zhu, Bing-Wei Chen, Qi-Guang Chen, Chun-Ti Shen, Yong-Yan Wang, Yun-Dai Chen, Zhong Wang

Publikováno v: Signal Transduction and Targeted Therapy, Vol 6, Iss 1, Pp 1-10 (2021)

Abstract It’s a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in the differentiated populations with complex diseases, as stable coronary heart disease. Here, in an adaptive,

Externí odkaz: https://doaj.org/article/cf6962dcbdc14cf8b0c251f367f1abd2

Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway

Autor: Hao Wang, Yu-chen Liu, Cheng-ying Zhu, Fei Yan, Meng-zhen Wang, Xiao-su Chen, Xiao-kai Wang, Bao-xu Pang, Yong-hui Li, Dai-hong Liu, Chun-ji Gao, Shu-jun Liu, Li-ping Dou

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-19 (2020)

Abstract Background Induction therapy for acute myeloid leukemia (AML) is an anthracycline-based chemotherapy regimen. However, many patients experience a relapse or exhibit refractory disease (R/R). There is an urgent need for more effective regimen

Externí odkaz: https://doaj.org/article/0a8d09fde8b042bd8c36f15349c63609

Investigation of Invigorating Qi and Activating Blood Circulation Prescriptions in Treating Qi Deficiency and Blood Stasis Syndrome of Ischemic Stroke Patients: Study Protocol for a Randomized Controlled Trial

Autor: Yu Wang, Ling Zhang, Yuan-jiang Pan, Wei Fu, Shu-wei Huang, Bin Xu, Li-ping Dou, Qun Hou, Chang Li, Li Yu, Hui-fen Zhou, Jie-hong Yang, Hai-tong Wan

Publikováno v: Frontiers in Pharmacology, Vol 11 (2020)

Ischemic stroke (IS) is characterized by high morbidity and high mortality. The integration of Traditional Chinese medicine (TCM) and western medicine has shown promising benefits in relieving symptoms, promoting neurological recovery, and improving

Externí odkaz: https://doaj.org/article/08c5a281ccaa43f19b550e9616d06085

[The Prognostic Value of FOSB Gene in Acute Myeloid Leukemia]

Autor: Song-Hua, Luan, Yan-Qing, Ma, Jing-Jing, Yang, Hao, Wang, Dai-Hong, Liu, Li-Ping, Dou

Publikováno v: Zhongguo shi yan xue ye xue za zhi. 30(4)

Objective: To analyze the expression of FOSB in acute myeloid leukemia （AML） and its correlation with prognosis of the patient based on the large sample data.The genome, transcriptome, gene chip and clinical information from multiple public datab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a37f33ef0716c67638c05f6b322d6e0f
https://pubmed.ncbi.nlm.nih.gov/35981363

Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway

Autor: Fei Yan, Cheng ying Zhu, Li ping Dou, Hao Wang, Baoxu Pang, Yong hui Li, Meng zhen Wang, Xiao kai Wang, Dai hong Liu, Yu chen Liu, Chun ji Gao, Shujun Liu, Xiao su Chen

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-19 (2020)
Journal of Experimental & Clinical Cancer Research : CR

Background Induction therapy for acute myeloid leukemia (AML) is an anthracycline-based chemotherapy regimen. However, many patients experience a relapse or exhibit refractory disease (R/R). There is an urgent need for more effective regimens to reve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bcbb054171b4b7172f1a15baf010cce
https://doaj.org/article/0a8d09fde8b042bd8c36f15349c63609